SEC Tracker
Get the app

Biovie BIVI

Biovie Q3 FY26: net loss $5.3M; diluted EPS −$0.70

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Biovie reported for Q3 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$5.3MAgainst −$2.8M in Q3 FY2510-Q income statement, on EDGAR
  2. Diluted EPS−$0.70Against −$0.15 in Q3 FY2510-Q income statement, on EDGAR
  3. Cash and cash equivalents$13.1M−43% from $23.2M in Q3 FY2510-Q balance sheet, on EDGAR
  4. Cash from operations−$7.4MAgainst −$1.3M in Q3 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Biovie files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. GT Biopharma GTBP public float $9M, Jun 30, 2025
  2. Talphera TLPH public float $8M, Jun 30, 2025
  3. Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025
  4. TherapeuticsMD TXMD public float $9M, Jun 30, 2025
  5. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025